These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25915849)

  • 1. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma.
    Riley MF; You MJ; Multani AS; Lozano G
    Oncogene; 2016 Jan; 35(3):358-65. PubMed ID: 25915849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis.
    Johnson J; Lagowski J; Lawson S; Liu Y; Kulesz-Martin M
    Oncogene; 2008 Apr; 27(19):2780-7. PubMed ID: 18026135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interplay between MDM2, p63/p73 and mutant p53.
    Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
    Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
    Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
    Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 suppresses p73 function without promoting p73 degradation.
    Zeng X; Chen L; Jost CA; Maya R; Keller D; Wang X; Kaelin WG; Oren M; Chen J; Lu H
    Mol Cell Biol; 1999 May; 19(5):3257-66. PubMed ID: 10207051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcellular distribution of p53 and p73 are differentially regulated by MDM2.
    Gu J; Nie L; Kawai H; Yuan ZM
    Cancer Res; 2001 Sep; 61(18):6703-7. PubMed ID: 11559539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer.
    Misra C; Majumder M; Bajaj S; Ghosh S; Roy B; Roychoudhury S
    Mol Carcinog; 2009 Sep; 48(9):790-800. PubMed ID: 19204927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible role of p73 on the modulation of p53 level through MDM2.
    Wang XQ; Ongkeko WM; Lau AW; Leung KM; Poon RY
    Cancer Res; 2001 Feb; 61(4):1598-603. PubMed ID: 11245471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of p53 and its homolog p73 by protoporphyrin IX.
    Sznarkowska A; Maleńczyk K; Kadziński L; Bielawski KP; Banecki B; Zawacka-Pankau J
    FEBS Lett; 2011 Jan; 585(1):255-60. PubMed ID: 21146529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
    Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
    Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
    Zhang L; Nie L; Maki CG
    Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
    Cipriano R; Patton JT; Mayo LD; Jackson MW
    Cell Cycle; 2010 Apr; 9(7):1373-9. PubMed ID: 20305378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes.
    Dohn M; Zhang S; Chen X
    Oncogene; 2001 May; 20(25):3193-205. PubMed ID: 11423969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential tumor suppressor p73 differentially regulates cellular p53 target genes.
    Zhu J; Jiang J; Zhou W; Chen X
    Cancer Res; 1998 Nov; 58(22):5061-5. PubMed ID: 9823311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.